bexarotene has been researched along with Metastase in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Craig, FE; Grandinetti, LM; Ho, J; Jedrych, J; Johnson, WT; Leeman-Neill, RJ; Patel, P | 1 |
| Qu, L; Tang, X | 1 |
| Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC | 1 |
| Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP | 1 |
| Altmeyer, P; Gambichler, T; Kreuter, A | 1 |
| Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP | 1 |
1 review(s) available for bexarotene and Metastase
| Article | Year |
|---|---|
Bexarotene: a promising anticancer agent.
Topics: Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Bexarotene; Cell Cycle; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Retinoid X Receptors; Tetrahydronaphthalenes | 2010 |
2 trial(s) available for bexarotene and Metastase
| Article | Year |
|---|---|
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Topics: Adult; Aged; Bexarotene; Carcinoma, Papillary; Cell Differentiation; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Thyroxine; Triiodothyronine | 2006 |
Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
Topics: Adult; Aged; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Tetrahydronaphthalenes; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2008 |
3 other study(ies) available for bexarotene and Metastase
| Article | Year |
|---|---|
Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.
Topics: Aged; Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Depsipeptides; Disease Progression; Drug Substitution; Fatal Outcome; Humans; Immunohistochemistry; Immunophenotyping; Lymphoma, T-Cell, Cutaneous; Male; Neoplasm Metastasis; Phenotype; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2016 |
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Cell Line, Tumor; Cell Movement; Endothelial Cells; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Retinoid X Receptors; Tetrahydronaphthalenes; Transplantation, Heterologous; Umbilical Cord | 2006 |
Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Diagnosis, Differential; Fatal Outcome; Female; Humans; Interferons; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Neoplasm Metastasis; Skin Neoplasms; Tetrahydronaphthalenes | 2006 |